Experience of measuring nasal nitric oxide (nNO) in a National Primary Ciliary Dyskinesia (PCD) Centre (2006-20)

A. Harris (Southampton (Hampshire), United Kingdom), H. Phan (Southampton (Hampshire), United Kingdom), F. Borca (Southampton (Hampshire), United Kingdom), S. Packham (Southampton (Hampshire), United Kingdom), A. Friend (Southampton (Hampshire), United Kingdom), H. Wilkins (Southampton (Hampshire), United Kingdom), A. Glen (Southampton (Hampshire), United Kingdom), W. Walker (Southampton (Hampshire), United Kingdom), J. Lucas (Southampton (Hampshire), United Kingdom)

Source: Virtual Congress 2020 – Mechanism or pathways of chronic lung diseases
Session: Mechanism or pathways of chronic lung diseases
Session type: E-poster session
Number: 2070
Disease area: Paediatric lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Harris (Southampton (Hampshire), United Kingdom), H. Phan (Southampton (Hampshire), United Kingdom), F. Borca (Southampton (Hampshire), United Kingdom), S. Packham (Southampton (Hampshire), United Kingdom), A. Friend (Southampton (Hampshire), United Kingdom), H. Wilkins (Southampton (Hampshire), United Kingdom), A. Glen (Southampton (Hampshire), United Kingdom), W. Walker (Southampton (Hampshire), United Kingdom), J. Lucas (Southampton (Hampshire), United Kingdom). Experience of measuring nasal nitric oxide (nNO) in a National Primary Ciliary Dyskinesia (PCD) Centre (2006-20). 2070

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Nasal nitric oxide (nNO) in paediatric primary ciliary dyskinesia (PCD) and in healthy children - On the lookout for optimal cut-off and reference range
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016


New portable nasal nitric oxide (nNO) analyser differentiates primary ciliary dyskinesia (PCD) from healthy individuals.
Source: International Congress 2017 – Primary ciliary dyskinesia and air pollution
Year: 2017


The use of exhaled nitric oxide (NO) to categorize asthma phenotype and treatment in children - Results from National Hospital of Pediatrics
Source: International Congress 2018 – Paediatric asthma: new mechanisms and tools
Year: 2018


Utility and validity of NO Vario Analyser® equipment for the determination of nitric oxide in exhaled air (FeNO)
Source: International Congress 2014 – Airway biomarkers
Year: 2014


Detection of primary ciliary dyskinesia by hand-held tidal breathing nasal nitric oxide measurements in a tertiary referral population
Source: International Congress 2014 – Prevention, diagnosis and consequences of respiratory infections in children
Year: 2014

Normal values of exhaled nitric oxide at 50 mL/s – A revisit
Source: International Congress 2014 – Systemic and airway biomarkers
Year: 2014

Correlation of fractional exhaled nitric oxide (FeNO) and peripheral blood eosinophils (PBE) in refractory asthma
Source: International Congress 2014 – Biomarkers of asthma and clinical immunology
Year: 2014


Alveolar nitric oxide (NO) in children born extremely preterm (EP)
Source: International Congress 2014 – Respiratory physiology and sleep disordered breathing in children
Year: 2014

Earlier use of fractional exhaled Nitric Oxide (FeNO) and challenge testing improves speed and accuracy of asthma diagnosis. MacLeod J, Respiratory Physiology, Bradshaw TA, Respiratory Medicine, Royal Infirmary of Edinburgh
Source: International Congress 2018 – Clinical and functional monitoring in airway disease
Year: 2018


The Relationship between Fractional exhaled nitric oxide (FeNO) and Asthma Control and Asthma Severity in Asthmatic Adults in Vietnam
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018

Economic evaluation of fractional exhaled nitric oxide (FENO) for the management of adult asthma in Spain
Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease
Year: 2015

L-Arginine metabolism in airways of children with primary ciliary dyskinesia (PCD) or cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014

Associations between fractional exhaled nitric oxide (FeNO), asthma, respiratory symptoms and self-reported allergies in female university students in Kobe, Japan
Source: International Congress 2015 – Risk factors and co-morbidities in asthma and COPD
Year: 2015

Repeatability of FeNO measurements with an airway inflammation monitor using the 6 second (6s) and the 10 second (10s) exhalation modes in children 6 to 10 years of age with asthma
Source: International Congress 2014 – Airway biomarkers
Year: 2014


Positive relationship between offline exhaled nitric oxide and lung clearance index in pre-school wheezers
Source: International Congress 2014 – Paediatric asthma: lung function testing and more
Year: 2014

Concomitant use of fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) as markers for predicting asthma exacerbation
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014

Measurement of exhaled nitric oxide in children, 2001: E. Baraldi and J.C. de Jongste on behalf of the Task Force
Source: Eur Respir J 2002; 20: 223-237
Year: 2002



Inducible nitric oxide synthase polymorphism in asthmatic patients
Source: International Congress 2014 – Basic and translational research in asthma and COPD
Year: 2014


Late Breaking Abstract - Management of asthma in pregnancy using fractional exhaled nitric oxide (FENO) to adjust inhaled corticosteroid (ICS) dose did not improve perinatal outcomes: the Breathing for Life Trial (BLT)
Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers
Year: 2020


Domiciliary diurnal variation of fractional exhaled nitric oxide (FeNO) for predicting short-term treatment effect
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016